Biotech | April 13, 2022
Switzerland grants conditional marketing authorisation for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
The total investment is in the region of Rs 200 crore
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The peptide-based vaccine induces a t cell-dependent response
Gomez joins Moderna from Dentsply Sirona, where he served as Executive Vice President & Chief Financial Officer since August 2019
The DRX-Compass helps navigate and accelerate towards superb performance with a solution that grows with its customers
Both companies have been selected for stand-by production by German government
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
The funding round is led by Kalaari Capital. Aflac Ventures, Digital Horizon, Stride Ventures, and existing investors also participated in the round
Subscribe To Our Newsletter & Stay Updated
